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Plasmid-mediated kanamycin resistance was detected in a strain ofMycobacterium abscessus subsp. bolletii responsible for a
nationwide epidemic of surgical infections in Brazil. The plasmid did not influence susceptibility to tobramycin, streptomycin,
trimethoprim-sulfamethoxazole, clarithromycin, or ciprofloxacin. Plasmid-mediated drug resistance has not been described so
far in mycobacteria.
Plasmid-mediated drug resistance is uncommon in mycobac-teria. A 56,267-bp circular plasmid of the broad-host-range
IncP-1 subgroup was detected in a strain of Mycobacterium ab-
scessus subsp. bolletii (formerly known as Mycobacterium massil-
iense [1] andMycobacterium abscessus subsp.massiliense [2]) that
was responsible for a nationwide outbreak of mycobacterial sur-
gical infections in Brazil in 2004 to 2008 (3, 4). This plasmid,
named pMAB01, contains a complete system for conjugative
DNA transfer and two genetic load regions carrying antimicrobial
resistance genes, including the Tn5393c streptomycin resistance
(str) transposon and a typical class 1 integron with an incorpo-
rated gene cassette encoding an aminoglycoside 6=-N-acetyltrans-
ferase (aac[6=]-Ib), the dihydropteroate synthase type 1 gene
(sul1), and a conserved open reading frame (orf5) that carries a
GCN5-likeN-acetyltransferase (3). We investigated the contribu-
tion of this plasmid to antimicrobial drug resistance inM. absces-
sus and in Escherichia coli.
The MICs of streptomycin (STR), kanamycin (KAN), tobra-
mycin (TOB), trimethoprim-sulfamethoxazole (SXT), clarithro-
mycin (CLR), and ciprofloxacin (CIP) were evaluated against the
prototype M. abscessus subsp. bolletii outbreak strain INCQS
00594, the INCQS 00594 strain cured of the plasmid after 10 in
vitro passages in liquid medium, and two additional outbreak iso-
lates, one harboring the pMAB01 plasmid and one lacking it (Fig.
1A). Two E. coli strains, BL21(DE3) and a spontaneous mutant of
E. coli C600 (5) showing nalidixic acid resistance (C600Nalr), and
the same strains harboring the pMAB01 plasmid were tested (Fig.
1B). The experiments performed to introduce pMAB01 intoE. coli
were detailed in a previous publication (3). In brief, competent E.
coli BL21(DE3) isolates were transformed by electroporation with
the pMAB01 plasmid purified from the INCQS 00594 isolate. In
addition, mating experiments were carried out to confirm the
conjugative capacity of the pMAB01 plasmid. Conjugative trans-
fer of pMAB01 fromM. abscessus to E. coli BL21(DE3) occurred at
a frequency of 5.24  108 transconjugants/recipient and from
the E. coli BL21(DE3) transconjugant to another E. coli strain,
C600Nalr, at a frequency of 1.14 106 transconjugants/recipient
(3). The E. coli C600Nalr strain was used as recipient in mating
experiments with two E. coli strains to simplify the screening of E.
coli transconjugants on nalidixic acid plates.
The MICs were determined by the broth microdilution method
according to Clinical and Laboratory Standards Institute docu-
ments M24-A2 and M100-S23 (6, 7). M. abscessus subsp. bolletii
was cultivated in cation-adjusted Mueller-Hinton broth (Oxoid,
Hampshire, United Kingdom) for 3 to 5 days at 30°C, and E. coli
was cultivated on LB agar plates for 16 h at 37°C. Bacterial suspen-
sionswere prepared and adjusted to a 0.5McFarland standard and
diluted to achieve a final inoculumof approximately 5 105CFU/
ml. The following drug concentrations were tested: 0.5 to 64
g/ml (STR, KAN, and TOB), 0.12 to 16 g/ml (CLR and CIP),
and 0.25/9.5 to 32/608g/ml (SXT). Staphylococcus aureusATCC
29213 was used as the control strain.
The MIC (g/ml) results are listed in Table 1. The plasmid
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FIG 1 Isolates included in the study. (A) M. abscessus subsp. bolletii isolates
obtained during the epidemic of surgical infections were typed by pulsed-field
gel electrophoresis (PFGE-DraI). Lane 1, isolate INCQS 00594; lane 2, cured
INCQS 00594 colony; lane 3, isolate CRM0019 obtained in 2006 in Rio de
Janeiro, Brazil; lane 4, isolate IAL2697 obtained in 2008 in São Paulo, Brazil.
The asterisks indicate the plasmid bands. (B) Plasmids from E. coli were ex-
tracted with a Qiagen plasmid minikit. LaneM, E. coliNCTC39 R861 (used as
marker); lane 1, E. coli BL21(DE3); lane 2, E. coli BL21(DE3) transformedwith
pMAB01; lane 3, transconjugant E. coli BL21(DE3); lane 4, E. coli C600Nalr;
and lane 5, transconjugant E. coli C600Nalr.
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contributed to the resistance of the M. abscessus subsp. bolletii
outbreak strain to KAN. However, all of the tested mycobacterial
isolates were resistant to other aminoglycosides, including STR
and TOB, regardless of the presence or absence of the pMAB01
plasmid, suggesting that chromosomally encoded mechanisms
may be responsible for resistance to these drugs in the outbreak
strains. This is supported by the fact that for transformed and
transconjugant E. coli BL21(DE3) and C600Nalr, pMAB01 was
associated with acquired resistance to all aminoglycosides tested,
while no or 1 log2 dilution variation was seen for STR and TOB
among plasmid-positive and -negativeM. abscessus subsp. bolletii
strains. In addition, previous publications have confirmed that
outbreak strains, whether harboring the pMAB01 plasmid or not,
are fully susceptible to amikacin (AMI) (MIC  4 g/ml or 8
g/ml) (8–10).
Acquired resistance to aminoglycosides in mycobacteria is
primarily based on modification of the 30S subunit of the ri-
bosome, caused by mutations in the 16S rRNA gene, rrs, or the
rpsL gene, which encodes the S12 ribosomal protein (11). Mu-
tations conferring resistance to 2-deoxystreptamine aminogly-
cosides in M. abscessus were identified at positions 1406, 1408,
1409, and 1491 in the rrs gene (12). InMycobacterium smegmatis,
changes in codons 43, 86, 88, and 91 of the S12 protein were
identified in streptomycin-resistantmutants (13). These substitu-
tions are not present in the rrs and rpsL genes from the INCQS
00594 strain (contigs 2 and 1, GenBank accession numbers
AUVF01000002 and AUVF01000001, respectively). The existence
of additional not-yet-identified mutations conferring aminogly-
coside resistance in rapidly growing mycobacteria cannot be dis-
regarded.
N-Acetylation and phosphorylation of a particular amino
group are chemical modifications of aminoglycoside antibiot-
ics that can result in decreased affinity of the drug for its target.
The complete genome sequence of M. abscessus ATCC 19977
(GenBank accession number CU458896) was annotated with 5
putative aminoglycoside phosphotransferase genes and one ami-
noglycoside 2=-N-acetyltransferase gene (14). The role of these
chromosomal enzymes in aminoglycoside resistance in mycobac-
teria has not been demonstrated (11). The plasmid pMAB01 car-
ries an aminoglycoside 6=-N-acetyltransferase, a GCN5-related
N-acetyltransferase (GNAT), and two str genes, encoding amin-
oglycoside-3=-O-phosphotransferase and aminoglycoside-6-O-
phosphotransferase, both ofwhich are required for high resistance
to streptomycin (15). The results obtained here indicate that chro-
mosomally and plasmid-encoded enzyme(s) contributed to KAN,
STR, and TOB resistance in theM. abscessus outbreak strain, while
in E. coli, the resistance was mediated solely by pMAB01-encoded
enzymes.
Despite the fact that all of the testedmycobacterial strains were
resistant to SXT, the MIC value of SXT was 4-fold higher in M.
abscessus isolates harboring the plasmid than in those lacking it.
The plasmid did not change the MIC of SXT in E. coli recipient
strains, which remained susceptible after the acquisition of
pMAB01, suggesting that the sul1 gene could be nonfunctional in
E. coli. sul1 is a dihydropteroate synthase (DHPS) type 1 gene that
catalyzes the formation of the immediate precursor of folic acid
and is implicated in resistance to sulfonamide. The type 2 enzyme
is stable, whereas type 1 DHPS loses its activity rapidly. This prop-
erty could explain the lack of activity of the DHPS in E. coli har-
boring the pMAB01 plasmid.T
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The MICs of CLR and CIP against M. abscessus subsp. bolletii
and E. coli were not affected by the presence or absence of
pMAB01, suggesting that nonspecific resistance mechanisms,
such as changes in cell wall permeability or the action of efflux
pumps, were not induced by this plasmid.
In conclusion, genetic exchange, especially the acquisition of
drug resistance promiscuous plasmids, could result in the emer-
gence of specificmycobacterial strains with altered resistance pro-
files, which might be better adapted to cause human disease. The
demonstration of plasmid-mediated resistance to KAN in an out-
break strain of M. abscessus suggests that the impact of resistance
plasmids in environmental mycobacteria deserves further investi-
gation.
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